Intravenous vs intraperitoneal mesenchymal stem cells administration: What is the best route for treating experimental colitis?

doi:10.3748/wjg.v20.i48.18228

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 48

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10462)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

743

WORD

234

HTML

5777

Figures (1-6)

287

Sum=7041

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1446

Download

1975

Sum=3421

Dec 28, 2014 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (60)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Dec 28, 2014; 20(48): 18228-18239
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18228

Full Size Figure Download Figure

Figure 4 Mesenchymal stem cells administered by intravenous injection promote histological improvement. Colon histology demonstrated intravenously administered mesenchymal stem cell (MSC) treatment reduced the extent of the inflamed area, crypt damage and infiltration of inflammatory cells. A: Hematoxylin-eosin (HE) staining. Scale bar: 200 μm; B: Histological score of colitis. ^aP < 0.05 vs Naive group, n = 5 mice/group.

Citation: Gonçalves FDC, Schneider N, Pinto FO, Meyer FS, Visioli F, Pfaffenseller B, Lopez PLDC, Passos EP, Cirne-Lima EO, Meurer L, Paz AH. Intravenous vs intraperitoneal mesenchymal stem cells administration: What is the best route for treating experimental colitis? World J Gastroenterol 2014; 20(48): 18228-18239
URL: https://www.wjgnet.com/1007-9327/full/v20/i48/18228.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i48.18228